Kornimate/medical-research-clean huggingface dataset:
using cerebrospinal fluid dynamics to optimize treatment of idiopathic normal pressure hydrocephalus

Conditions: Hydrocephalus, Normal Pressure

Summary: the purpose of the study is to determine if the so called pulsatility curve, which describes the relationship between intracranial pressure (icp) and icp pulsatility, can be used to predict outcome of treatment, in the form of shunt surgery, in idiopathic normal pressure hydrocephalus (inph) and to guide the adjustment of shunt opening pressure after the surgery. the main hypotheses of the study are: 1. the pulsatility curve may be the best auxiliary test to predict shunt surgery outcome in inph patients. with a "fixed" shunt opening pressure, the preoperatively assessed potential pulse amplitude reduction (determined by analysis of the pulsatility curve) predicts postoperative improvement in gait velocity and cognitive functions. 2. a postoperative pulsatility curve can be used to further optimize icp pulsatility by guiding opening pressure adjustment. shunt adjustment based on the pulsatility curve three months postoperatively will increase improvement, but not complications, compared to a shunt with "fixed" opening pressure. based on these hypotheses, three specific aims for the study have been defined: 1. to determine if improvement three month after surgery is associated with postoperative reduction in pulse amplitude. 2. to determine if a pulsatility curve obtained preoperatively can predict improvement in gait velocity and cognitive functions in inph patients three months after surgery. 3. to compare outcome six months after surgery and complications rates between inph patients with a "fixed" opening pressure versus those where the shunt has been adjusted based on the pulsatility curve, three months after the shunt insertion.


Eligibility criteria:
inclusion criteria: * possible or probable inph according to the inph guidelines. * symptom duration ≥ 3 months * age ≥50 years * able to walk 10 meters with or without an assistant device. * decision to recommend shunt surgery based either on: * improvement after cerebrospinal fluid (csf) tap (i.e. positive tap test), or; * increased csf outflow resistance, or; * a combination of "typical" signs/symptoms + "typical" mri findings; * a combination of a-c. exclusion criteria: * nph due to hemorrhage, meningitis or stroke (secondary nph). * symptom duration ≥ 5 years. * patients considered surgical risk. * baseline gait velocity \>1.1 m/sec (60 m/min) without assistant device * mini mental state exam score ≤ 20 points. * musculoskeletal condition precluding gait assessment. * severe hearing or visual impairment * medication in the form of warfarin or novel oral anticoagulant (noac) * insufficient pressure data below resting pressure during the csf infusion investigation, i.e. no complete assessment of the pulsatility curve
a collaborative double-blind placebo-controlled trial of intravenous ribavirin as a treatment for presumed hantavirus pulmonary syndrome

Conditions: Hantavirus Pulmonary Syndrome

Summary: the purpose is to test the safety and effectiveness of intravenous ribavirin therapy in persons with suspected and subsequently proven hantavirus infection. the hantavirus is spread through the air into the lungs when dry rodent feces are moved or disturbed. it is characterized by fever and bleeding.

patients are randomized to receive either ribavirin or a placebo for 7 days. at the completion of therapy, patients will be seen on follow-up visits on days 14, 28, and 84.

Eligibility criteria:
inclusion criteria: you may be eligible for this study if you: * are 12 years of age or older. * are not pregnant. * agree to practice sexual abstinence or use accepted barrier methods of birth control/contraception. * are not breast-feeding. * have a positive blood test for hantavirus. * have symptoms suggestive of hantavirus illness. exclusion criteria: you will not be eligible for this study if you: * have severe low blood count (anemia). * have a diagnosis of other respiratory viruses (influenza, rsv, etc.). * have group a streptococcus with symptoms of streptococcal pharyngitis, a positive culture from a normally sterile site, or symptoms of bacterial pneumonia. * are hiv positive. * have cancer. * have had any period of irregular heartbeat. * have had chemotherapy or other drugs that suppress the immune system within 30 days. * have taken by mouth or injection any antiviral drug (other than acyclovir, famciclovir, amantadine or rimantadine.) * have taken by mouth or injection corticosteroids equivalent to approximately 0.5 mg/kg prednisone. * have taken any experimental drug within 30 days prior to enrollment.
3d printing for nodule localization

Conditions: Pulmonary Nodule, Solitary; Lung Cancer

Summary: implementation of lung cancer screening using low-dose computed tomography has increased the rate of detection of small peripheral pulmonary nodules. however, it is hard to localize these nodules by palpation because of their small volume and long distance to the nearest pleural surface. to further clarify the confounding factors, we developed our own 3d printing localization procedure. in contrast to traditional ct-g percutaneous puncture localization, our procedure was performed in the operating room without ct scan evaluation.

pulmonary wedge resection is one of the most common types of operations performed by thoracic surgeons, especially given that more and more patients with ground glass nodules are being detected recently. one of the most significant current discussion concerning wedge resection is nodule localization. at present, a commonly used localization method is the ct-guided percutaneous lung puncture methylene blue staining marker localization, but this method has two main disadvantages: 1. the methylene blue dye is easy to spread, affecting the intraoperative judgment of nodule position by surgeon; 2. patients often suffer additional ct radiation. in recent years, the three-dimensional (3d) printing technique has been gradually applied to clinical therapy. however, 3d-printed template-guided (3d-g) localization required pre-evaluation by ct scanning. if deviation of more than 2 cm was found on the ct scan, the 3d-g method was regarded as a failure and traditional ct-g hookwire localization was used. to further clarify the confounding factors, the investigators developed their own 3d printing localization procedure. in contrast to traditional ct-g percutaneous puncture localization, the 3d printing localization procedure was performed in the operating room without ct scan evaluation.

Eligibility criteria:
inclusion criteria: * a maximum target lung nodule diameter ≤20 mm; * a target nodule consolidation/tumor ratio (ctr) \ 10 mm if the target nodule ctr was \>0.25. exclusion criteria: * inability to comply with research protocols or research procedures * any unstable systemic disease (including active infections, uncontrolled high blood pressure, unstable angina, angina pectoris that has started within the last 3 months, congestive heart failure (≥ new york heart association \[nyha\] level ii ), cardiac infarction (6 months before enrollment), severe arrhythmia requiring medication, liver, kidney or metabolic disease * active bleeding; inability to withstand lying flat; inability to cooperate through breathing during puncture * pregnant or lactating women * other circumstances that the investigator believes are not suitable for enrollment

Keywords: pulmonary nodules lung neoplasms computed tomography three-dimensional printing
a study to investigate an immunomodulatory therapy in adult patients with perennial allergic rhinoconjunctivitis

Conditions: Perennial Allergic Rhinoconjunctivitis; House Dust Mite Allergy

Summary: the purpose of the study is to test the efficacy of the combination treatment allqbg10 in patients with perennial allergic rhinoconjunctivitis due to house dust mite allergy in a double-blind placebo-controlled setting


Eligibility criteria:
inclusion criteria: * mild to moderate perennial allergic rhinoconjunctivits due to hypersensitization towards house dust mite allergens exclusion criteria: * clinically relevant other allergies (perennial or seasonal) that could potentially interfere with the patient's study treatment schedule or assessments * use of any concomitant medication that could affect the patient's study treatment response or assessment results
1-year follow up to the 1473-imiq study

Conditions: Keratosis

Summary: this is a 1-year follow-up study to evaluate the long-term effects in subjects who completely cleared their actinic keratosis (ak) lesions in the 1473-imiq study. the 1473-imiq study evaluated the safety and effectiveness of imiquimod 5% cream compared to a placebo cream for the treatment of ak.


Eligibility criteria:
inclusion criteria: * subject had to participate in the 1473-imiq study and have had 100% clearance of ak lesions exclusion criteria: * did not use any topical preparations in the previous treatment area within 24-hours of the scheduled visit.

Keywords: ak imiquimod 5% cream 3m pharmaceuticals aldara actinic keratosis
clinical proteomic research for the brain

Conditions: Ischemic Brain Injury; Stroke; Healthy Individual; Patent Foramen Ovale (PFO); Neurovascular Injury

Summary: the study of plasma and urine proteomic profiles in patients with ischemic brain injury is important to better understanding of the mechanisms by which thrombolytic agents or other therapy affects clinical outcomes. the purpose of this study is to study the proteomic profile of patients with ischemic brain injury and compare it to control subjects without ischemic brain injury, subjects with other chronic neurologic diseases or systemic vascular diseases, and pre- and post- therapy which may be associated with, or predictive of, therapeutic outcome. the investigators hypothesize that there is a unique set of proteins expressed in serum and urine in patients with ischemic brain injury that may provide a more complete understanding of ischemic brain injury pathophysiology. ultimately, this study may provide information of direct relevance to the medical care of a large proportion of patients with ischemic brain injury and other neurologic diseases in the future. and proteomic proteomic profile may provide important information about the roles of specific biomarkers. perhaps the prevention of ischemic injury related complications.


Eligibility criteria:
case inclusion and exclusion criteria: inclusion criteria: 1. ischemic brain injury within 12 hours of symptom onset; 2. including primary ischemic brain injury from embolism or arterial occlusion or secondary due to increased icp after trauma, subarachnoid hemorrhage. exclusion criteria: 1. patients who are hemodynamically unstable for venipunctures; 2. anemic patients (hemoglobin \< 11); 3. children; 4. pregnant women. controls inclusion and exclusion criteria: inclusion criteria: 1. healthy adults without any neurologic or systemic disease; 2. inpatient or outpatient adults with a chronic stroke (greater than 3 months) or chronic neurologic disease such as neurodegenerative disease, movement disorder, demyelinating disease; 3. inpatient or outpatient adults with systemic vascular disease. exclusion criteria: 1. patients who are hemodynamically unstable for venipunctures; 2. anemic patients (hemoglobin \< 11); 3. children; 4. pregnant women.

Keywords: patient foramen ovale pfo stroke ischemic brain injury neurovascular disease
improving diabetes after bariatric surgery

Conditions: Obesity; Diabetes

Summary: the goal of this project is to examine the physical mechanisms that contribute to improvements of glucose tolerance in type 2 diabetes mellitus (dm) following certain types of bariatric surgery.

the goal of this project is to examine the physiological mechanisms that contribute to improvements of glucose homeostasis in type 2 diabetes mellitus (dm) following gastric bypass roux-en-y bariatric surgery (gbp). the central hypotheses are: 1) that surgical changes in the anatomy of nutrient absorption achieved by gbp change incretin hormone secretion which in turn improves pancreatic islet function; and 2) that improvement in insulin secretion induced by the changes in incretin function, together with improvement in insulin resistance induced by weight loss, normalize glucose homeostasis in type 2 dm. funds are not available to pay for the surgery for patients, only to address research questions.

Eligibility criteria:
inclusion criteria: * patients who are at least 18 years of age and undergo bariatric surgery by a labs certified surgeon. * enrollment in labs-1 or labs-2. * documented type 2 diabetes (fasting plasma glucose greater than 125 mg/dl) that is treated with lifestyle efforts (drug naïve) or taking acceptable oral medications (see appendix) with a hga1c less than or equal to 8.5% and a fasting blood glucose less than or equal to 180 mg/dl. this will be one group. * non-diabetic (nd) with normal values for fasting glucose and hba1c. this will be the second group. * adequate iv access. exclusion criteria: * informed consent not obtained. * patient with diabetes with an hba1c greater than 8.5% or a fasting blood glucose greater than 180 mg/dl. * creatinine greater than 1.7. * unlikely to comply with the 6 month follow-up (post-surgical) protocol (i.e. geographically inaccessible for study visits) or unable to communicate with local study staff. * use of unacceptable diabetic medications (see appendix) at baseline (see appendix).
single injection of regn475/sar164877 in the treatment of chronic pancreatitis pain

Conditions: Abdominal Pain Upper

Summary: primary objective was to demonstrate the activity of regn475/sar164877 in reducing the pain associated with chronic pancreatitis. secondary objectives were: * to assess the safety and tolerability of regn475/sar164877 in patients with chronic pancreatitis pain; * to characterize the pharmacokinetic, pharmacodynamic, and immunogenicity profiles of regn475/sar164877 in this population; * to measure the change in the total daily dose of rescue medications required.

the duration of the study period for each participant was up to 14 weeks, including a screening period up to 2 weeks, and 12-week follow-up after the injection.

Eligibility criteria:
inclusion criteria: * moderate to severe abdominal pain due to chronic pancreatitis of at least 6 months duration. exclusion criteria: * mild pain on the pain intensity-numeric rating scale \[pi-nrs\] at screening and randomization visits; * narcotic addiction; * recent pancreatic surgical or endoscopic intervention for chronic pancreatitis pain; * unwillingness to use study-defined rescue analgesia exclusively. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
persistent cardiovascular effects of covid-19 viral infection trial (perceive)

Conditions: Heart Failure

Summary: this is a prospective study in which a process of identifying and improving a reduction of functional capacity in covid-19 survivors \>50 years old. the overall goal of this study to identify the feasibility and value of risk-guided medical therapy and exercise intervention in covid-19 survivors.

participants enrolled in this study will be randomized to a cardio-covid disease management plan (cc-dmp) that involves the use of vo2 testing and surveillance imaging to detect reduced functional capacity and subclinical left ventricular dysfunction (lvd), clinical review to ensure optimal risk factor control and cardio-protection and exercise intervention. the program will be delivered over a period of 24 months. the outcome from this study will show that subclinical lvd is common among covid-19 survivors, and a cc-dmp is feasible in reducing hf risk factors in this sub group of survivors.

Eligibility criteria:
inclusion criteria: 1. history of covid-19 infection 2. live within a geographically accessible area for follow-up exclusion criteria: 1. valvular stenosis or regurgitation of \>moderate severity 2. history of previous heart failure (baseline new york heart association (nyha) classification \>2) 3. inability to acquire interpretable images (identified from baseline echo) 4. contraindications to beta blockers or angiotensin-converting enzyme inhibitors 5. oncologic (or other) life expectancy \<12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the chief investigators) that it is not appropriate for the patient to participate in this trial 6. already taking both angiotensin converting enzyme inhibitors/ angiotensin receptor blockers and beta blockers, or intolerance (or allergy) to both. 7. mobility impairment that would impact participants' ability to perform exercise 8. unable to provide written informed consent to participate in this study

Keywords: heart failure covid
bay59-7939 japanese in atrial fibrillation (2nd)

Conditions: Atrial Fibrillation

Summary: this study was a randomized, parallel group, open label trial using warfarin as comparator. pharmacokinetics (pk) and pharmacodynamics (pd) were investigated only in bay59-7939 groups (originally described in japanese).


Eligibility criteria:
inclusion criteria: * japanese subjects with non-valvular af who met all of the following criteria: * persistent or paroxysmal non-valvular af with \>/=2 episodes before enrollment, at least 1 of which had been verified by ecg recording within 4 weeks before randomization * male subjects aged 20 years or older and postmenopausal female subjects * subjects with at least one risk factor for thromboembolism or aged 60 years or older (risk factor for thromboembolism: hypertension, diabetes mellitus, coronary artery disease, congestive heart failure). exclusion criteria: * history or presence of stroke or transient ischemic attack. * history of intracerebral hemorrhage. * history or presence of bleeding at randomization; intraocular or gastrointestinal bleeding within the last 6 months prior to randomization.

Keywords: bay59-7939 rivaroxaban non-valvular atrial fibrillation japanese patients phase ii
effects of concentric exercise with and without mulligan wrist mobilization after distal radius fracture.

Conditions: Distal Radius Fracture

Summary: the distal end of the radius is defined as the area three centimeters proximal to the radio carpal joint, where the radius interfaces with the lunate and scaphoid bone of the wrist. a fracture of the distal radius is usually caused by falling on the outstretched arm. the majority of distal radial fractures are closed injuries in which the overlying skin remains intact. pain, swelling, bruising, deformity and deformity in the forearm or wrist are common. in women, the incidence of distal radial fracture increases with age from 40 years. the objective of this study will be to determine the effects of concentric exercises with and without mulligan wrist mobilization on pain, grip strength, range of motion and function after distal radius fracture. this study will be a randomized controlled trial and will be conducted in district head quarter hospital sheikhupura. the study will be completed in time duration of six months after the approval of synopsis and convenience sampling technique will be used. 18 subjects will be divided in two groups. group a will follow concentric exercises at wrist including flexion, extension, abduction, adduction, pronation, supination and wrist mobilizations with movements while group b will follow only wrist concentric exercises treatment. mwm based on mulligan's recommendation that the patient should not experience any pain. the location and direction of the glide could be modified so that the mwm was pain free, as advocated in the mulligan concept. this study will be of 4 weeks, 3 sessions per week. data will be collected by all participants before 1st session after 6th session and at the end of 12th session by using nprs, hand dynamometer, goniometer and patient rated wrist evaluation score. data will be analyzed by spss-25.


Eligibility criteria:
inclusion criteria: * age: 35-70 years * subjects with at least 6 weeks of distal radius fracture * orthopedic surgeon advise exclusion criteria: * neurological problem affecting upper limb * parkinson disease * subjects having polyarthritis, bleeding disorders, tumors, local infection, peripheral vascular disease * any contraindication to physiotherapy

Keywords: disability range of movement concentric exercises movement fracture
cprit: patient adherence to lung cancer screening

Conditions: Lung Cancer Screening

Summary: to understand participants' barriers to lung cancer screening and their experience with scheduling lung cancer screening.

primary objectives/aims 1. determine rates of lung cancer scheduling and screening at the utmb and ut tyler lcs programs. 2. using state-of-the-art machine learning (ml) approaches, develop prediction models for adherence to screening guidelines for newly eligible and established patients. investigators will leverage data from brfss, ut tyler and utmb to develop and validate the prediction model, ensuring its generalizability and accuracy. 3. survey participants in the lcs programs about their impressions and experience with the scheduling and completing screening; conduct interviews with participants who receive an order for lcs but do not complete screening by their due date. 4. interview lcs program directors and staff about barriers and facilitators of increasing screening rates in their programs.

Eligibility criteria:
inclusion criteria: * current smoker or quit within the past 15 years * a 20+ pack-year smoking history * healthy enough for treatment exclusion criteria: * not applicable as our focus is on patients with an order for screening at the utmb or ut tyler
gefitinib combined with radiotherapy in elderly patients with esophageal cancer

Conditions: Esophageal Cancer

Summary: elderly patients with esophageal cancer will receive thoracic radiation therapy 54-60gy over 30 fractions, and concurrent with gefitinib.

purpose: to evaluate the efficacy and toxicity of a concomitant treatment using egfr-tki and thoracic radiation in elderly patients with esophageal cancer. methods:patients(\>70 years old) with esophageal cancer will receive thoracic radiation therapy 54-60 gy over 30 fractions and concurrent with gefitinib 250mg/day.

Eligibility criteria:
inclusion criteria: * histologically documented diagnosis of esophageal cancer * disease must be encompassed in a radiotherapy field.patients with celiac, perigastric, mediastinal or supraclavicular adenopathy are eligible * age:70-85 years * written informed consent. * performance status of 0 to 2 * neutrophil count \>1.5 x 10 to the 9th power/l and platelets \> 100 x 10 to the 9th power/l. * hepatic: total bilirubin less than or equal to 1.5 times upper limit of normal (uln) alanine transaminase (alt) and aspartate transaminase (ast) less than or equal to 2.5 times uln (or less than or equal to 5 times uln in case of known liver involvement * renal: serum creatinine less than or equal to 1.5 times upper limit of normal (uln) exclusion criteria: * evidence of tracheoesophageal fistula, or invasion into the trachea or major bronchi. * prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 2 years (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible). * prior systemic chemotherapy or radiation therapy for esophageal cancer

Keywords: gefitinib radiation esophageal cancer